Publications by authors named "Ethan D Miller"
Article Synopsis
- - Immune checkpoint inhibitors (ICIs) are effective cancer treatments but can cause unique liver injuries known as immune-mediated liver injury caused by checkpoint inhibitors (ILICI), which differ from typical drug-induced liver injuries.
- - There is a lack of standardized best practices for managing ILICI during drug development, even though awareness and guidelines for these immune-related adverse effects are increasing.
- - This publication provides recommendations for monitoring, diagnosing, and managing ILICI in clinical trials, focusing on best practices related to liver test monitoring, detection, causality assessment, and treatment protocols.
Introduction: We conducted this study to characterize the incidence, clinical features, treatment, and outcomes of immune checkpoint inhibitor (ICI) hepatotoxicity.
Methods: Patients who received ICIs (with either single-agent or combination regimens) from January 1, 2010, to March 31, 2018, were identified. Hepatotoxicity was defined as alanine aminotransferase (ALT) >5 times the upper limit of normal (ULN), in the absence of an alternate cause, and categorized as grade 3 (ALT 5-20× ULN) or grade 4 (ALT >20× ULN), according to Common Terminology Criteria for Adverse Events 4.
Background: Quality of life (QOL) is impaired in pancreatic cancer patients. Our aim was to investigate the determinants and prognostic value of QOL after diagnosis in a hospital-based cohort of racially/ethnically diverse patients with pancreatic ductal adenocarcinoma (PDAC).
Patients And Methods: QOL was prospectively assessed using the Short Form-12 in 2478 PDAC patients.
The use of direct-acting antiviral agents (e.g., telaprevir, boceprevir) has improved response rates in patients with hepatitis C virus (HCV) genotype 1 infections.
View Article and Find Full Text PDFGoals: To underscore the utility of DNA fingerprinting for clarifying disparate results from endoscopic pathologic specimens.
Background: Occasionally, serially obtained gastrointestinal biopsies may yield inconsistent results. These discrepancies pose a dilemma for gastroenterologists and their patients, especially when malignancy is a consideration.